The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
Open accessAbstract
Importance: The age-based or "one-size-fits-all" breast screening approach does not take into account the individual variation in risk. Mammography screening reduces death from breast cancer at the cost of overdiagnosis. Identifying risk-stratified screening strategies with a more favorable ratio of overdiagnoses to breast cancer deaths prevented would improve the quality of life of women and save resources. Objective: To assess the benefit-to-harm ratio and the cost-effectiveness of risk-stratified breast screening programs compared with a standard age-based screening program and no screening. Design, Setting, and Population: A life-table model was created of a hypothetical cohort of 364 500 women in the United Kingdom, aged 50 years, with follow-up to age 85 years, using (1) findings of the Independent UK Panel on Breast Cancer Screening and (2) risk distribution based on polygenic risk profile. The analysis was undertaken from the National Health Service perspective. Interventions: The modeled interventions were (1) no screening, (2) age-based screening (mammography screening every 3 years from age 50 to 69 years), and (3) risk-stratified screening (a proportion of women aged 50 years with a risk score greater than a threshold risk were offered screening every 3 years until age 69 years) considering each percentile of the risk distribution. All analyses took place between July 2016 and September 2017. Main Outcomes and Measures: Overdiagnoses, breast cancer deaths averted, quality-adjusted life-years (QALYs) gained, costs in British pounds, and net monetary benefit (NMB). Probabilistic sensitivity analyses were used to assess uncertainty around parameter estimates. Future costs and benefits were discounted at 3.5% per year. Results: The risk-stratified analysis of this life-table model included a hypothetical cohort of 364 500 women followed up from age 50 to 85 years. As the risk threshold was lowered, the incremental cost of the program increased linearly, compared with no screening, with no additional QALYs gained below 35th percentile risk threshold. Of the 3 screening scenarios, the risk-stratified scenario with risk threshold at the 70th percentile had the highest NMB, at a willingness to pay of £20 000 (US $26 800) per QALY gained, with a 72% probability of being cost-effective. Compared with age-based screening, risk-stratified screening at the 32nd percentile vs 70th percentile risk threshold would cost £20 066 (US $26 888) vs £537 985 (US $720 900) less, would have 26.7% vs 71.4% fewer overdiagnoses, and would avert 2.9% vs 9.6% fewer breast cancer deaths, respectively. Conclusions and Relevance: Not offering breast cancer screening to women at lower risk could improve the cost-effectiveness of the screening program, reduce overdiagnosis, and maintain the benefits of screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The benefits and harms of breast cancer screening: an independent review
Marmot, M. G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61611-0 · Cited by 1,495
Association analysis identifies 65 new breast cancer risk loci
Michailidou, K., Lindström, S., Dennis, J., Beesley, J., Hui, S., Kar, S., Lemaçon, A., Soucy, P., Glubb, D. M., Rostamianfar, A., et al. (2017) · Nature · doi:10.1038/nature24284 · Cited by 1,380
Higgins (2002) · doi:10.1002/(issn)1097-0258 · Cited by 1,248
Polygenic susceptibility to breast cancer and implications for prevention
Pharoah, P. D. P., Antoniou, A. C., Bobrow, M., Zimmern, R. L., Easton, D. F., & Ponder, B. A. J. (2002) · Nature Genetics · doi:10.1038/ng853 · Cited by 898
Self-citationMaas, P., Barrdahl, M., Joshi, A. D., Auer, P. L., Gaudet, M. M., Milne, R. L., Schumacher, F. R., Anderson, W. F., Check, D., Chattopadhyay, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1025 · Cited by 373
Schousboe, J. T., Kerlikowske, K. M., Loh, A., & Cummings, S. R. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-1-201107050-00003 · Cited by 317
Duffy, S. W., Chen, H., Tabár, L. K., & Day, N. E. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141404 · Cited by 208
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
Pashayan, N., Duffy, S. W., Chowdhury, S., Dent, T., Burton, H., Neal, D. E., Easton, D. F., Eeles, R. A., & Pharoah, P. D. P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.118 · Cited by 160
Self-citationEvans, D. G., Astley, S., Stavrinos, P., Harkness, E. F., Donnelly, L. S., Dawe, S., Jacob, I., Harvie, M., Cuzick, J. M., Brentnall, A. R., et al. (2016) · Programme Grants for Applied Research · doi:10.3310/pgfar04110 · Cited by 153
Cost-Effectiveness and Harm-Benefit Analyses of Risk-Based Screening Strategies for Breast Cancer
Vilaprinyó, E., Forné, C., Carles-Lavila, M., Sala, M., Pla, R., Castells, X., Domingo, L., Rué, M., & the Interval Cancer (INCA) Study Group (2014) · PLoS ONE · doi:10.1371/journal.pone.0086858 · Cited by 142
Flagged first, then by citations
Research works printed but not linked: 1
- Dent, 2014, Stratified Screening for Cancer: Recommendations and Analysis From the COGS Project
Cited by
Sorted by citations
Items 101–200 of 284
Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection
Šehović, E., Urru, S., Chiorino, G., & Doebler, P. (2022) · BMC Cancer · doi:10.1186/s12885-022-09698-8 · Cited by 22
Tan, N. Q. P., Nargund, R. S., Douglas, E. E., Lopez-Olivo, M. A., Resong, P. J., Ishizawa, S., Nofal, S., Krause, K. J., Volk, R. J., & Toumazis, I. (2025) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00278-0 · Cited by 19
The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review
Bourke, M., McInerney-Leo, A. M., Steinberg, J., Boughtwood, T. F., Milch, V., Ross, A. L., Ambrosino, E., Dalziel, K., Franchini, F., Huang, L., et al. (2025) · Applied Health Economics and Health Policy · doi:10.1007/s40258-025-00949-w · Cited by 19
Breast cancer screening program for risk groups: facts and perspectives
Marques, C. A. V., de Figueiredo, E. N., & de Gutiérrez, M. G. R. (2021) · Revista Brasileira de Enfermagem · doi:10.1590/0034-7167-2021-0050 · Cited by 19
Evans, D. G., McWilliams, L., Astley, S., Brentnall, A. R., Cuzick, J. M., Dobrashian, R., Duffy, S. W., Gorman, L. S., Harkness, E. F., Harrison, F., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02250-w · Cited by 19
Dagan, N., Magen, O., Leshchinsky, M., Makov-Assif, M., Lipsitch, M., Reis, B. Y., Yaron, S., Netzer, D., & Balicer, R. D. (2024) · NEJM AI · doi:10.1056/aioa2300012 · Cited by 19
Lindsay, D., Bell, K., Olsen, C. M., Whiteman, D. C., Pathirana, T., & Collins, L. G. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae296 · Cited by 19
Marino, M. M., Rienzo, M., Serra, N., Marino, N., Ricciotti, R., Mazzariello, L., Leonetti, C. A., Ceraldi, M. P., Casamassimi, A., Capocelli, F., et al. (2019) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2018.0328 · Cited by 19
Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores
Padrik, P., Tõnisson, N., Hovda, T., Sahlberg, K. K., Hovig, E. J., Costa, L., Nogueira-Costa, G., Feldman, I., Sampaio, F., Pajusalu, S., et al. (2025) · Cancers · doi:10.3390/cancers17071056 · Cited by 18
Smith, J., Cust, A. E., & Lo, S. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad275 · Cited by 19
Harrison, H., Li, N., Saunders, C. L., Rossi, S., Dennis, J., Griffin, S. J., Stewart, G. D., & Usher-Smith, J. (2022) · BJU International · doi:10.1111/bju.15752 · Cited by 15
Pickles, K. M., Hersch, J. K., Nickel, B., Vaidya, J. S., McCaffery, K. J., & Barratt, A. L. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061211 · Cited by 17
Noguchi, N., Marinovich, M. L., Wylie, E. J., Lund, H., & Houssami, N. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51216 · Cited by 17
Kadom, N., Itri, J. N., Trofimova, A. V., Otero, H. J., & Horný, M. (2018) · Academic Radiology · doi:10.1016/j.acra.2018.10.014 · Cited by 17
Personalised and risk based cancer screening
Autier, P. (2019) · BMJ · doi:10.1136/bmj.l5558 · Cited by 17
Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population
Ficorella, L., Yang, X., Mavaddat, N., Carver, T. J., Hassan, H., Dennis, J., Tyrer, J. P., Ho, W.-K., Teo, S., Hartman, M., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03117-y · Cited by 16
Self-citationHamid, M. T. R., Mumin, N. A., Wong, Y. V., Chan, W. Y., Rozalli, F. I., & Rahmat, K. (2023) · Clinical Radiology · doi:10.1016/j.crad.2023.03.006 · Cited by 16
Padrik, P., Puustusmaa, M., Tõnisson, N., Kolk, B., Saar, R., Padrik, A., & Tasa, T. (2023) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234231205700 · Cited by 16
Albeshan, S. M., Hossain, S. Z., Mackey, M., Peat, J. K., Tahan, F. M. A., & Brennan, P. (2019) · Clinical Imaging · doi:10.1016/j.clinimag.2019.01.002 · Cited by 15
A response to “Personalised medicine and population health: breast and ovarian cancer”
Antoniou, A. C., Anton‐Culver, H., Borowsky, A. D., Broeders, M. J. M., Brooks, J. D., Chiarelli, A. M., Chiquette, J., Cuzick, J. M., Delaloge, S., Devilee, P., et al. (2019) · Human Genetics · doi:10.1007/s00439-019-01984-z · Cited by 15
Self-citationMukama, T., Fallah, M., Tian, Y., Sundquist, K., Sundquist, J., Brenner, H., & Kharazmi, E. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.011 · Cited by 15
Yiangou, K., Kyriacou, K. C., Kakouri, E., Marcou, Y., Panayiotidis, M. I., Loizidou, M. A., Hadjisavvas, A., & Michailidou, K. (2021) · Cancers · doi:10.3390/cancers13184568 · Cited by 15
Bhatt, R., van den Hout, A., Antoniou, A. C., Shah, M., Ficorella, L., Steggall, E., Easton, D. F., Pharoah, P. D. P., & Pashayan, N. (2024) · Cancer · doi:10.1002/cncr.35183 · Cited by 14
Self-citationYiangou, K., Mavaddat, N., Dennis, J., Zanti, M., Wang, Q., Bolla, M. K., Abubakar, M., Ahearn, T. U., Andrulis, I. L., Anton‐Culver, H., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01947-x · Cited by 24
Purvis, R., Forrest, L. E., Young, M., Limb, S., James, P. A., & Taylor, N. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101414 · Cited by 14
Schmutzler, R. K., Schmitz‐Luhn, B., Borisch, B., Devilee, P., Eccles, D., Hall, P. N., Balmañà, J., Boccia, S., Dabrock, P., Emons, G., et al. (2021) · Breast Care · doi:10.1159/000517182 · Cited by 14
Self-citationRoh, S., Lee, Y.-S., Kenyon, D. B., Elliott, A. J., Petereit, D. G., Gaba, A. G., & Lee, H. Y. (2023) · JMIR Formative Research · doi:10.2196/47851 · Cited by 13
An optimization framework to guide the choice of thresholds for risk-based cancer screening
Brentnall, A. R., Atakpa, E. C., Hill, H. R., Santeramo, R., Damiani, C., Cuzick, J. M., Montana, G., & Duffy, S. W. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00967-9 · Cited by 14
Bromley, H. L., Petrie, D., Mann, G. B., Nickson, C., Rea, D. W., & Roberts, T. E. (2019) · Social Science & Medicine · doi:10.1016/j.socscimed.2019.03.028 · Cited by 13
Willingness to decrease mammogram frequency among women at low risk for hereditary breast cancer
Guan, Y., Nehl, E. J., Pencea, I., Condit, C. M., Escoffery, C., Bellcross, C. A., & McBride, C. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45967-6 · Cited by 13
Opportunities in cancer imaging: risk-adapted breast imaging in screening
Gilbert, F. J., Hickman, S. E., Baxter, G. C., Allajbeu, I., James, J. J., Caraco, C., & Vinnicombe, S. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.02.013 · Cited by 13
Self-citationHou, C., Xu, B., Hao, Y., Yang, D., Song, H., & Li, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09425-3 · Cited by 13
Polygenic risk scores to stratify cancer screening should predict mortality not incidence
Vickers, A. J., Sud, A., Bernstein, J. L., & Houlston, R. S. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00280-w · Cited by 12
Lapointe, J., Côté, J.-M., Mbuya-Bienge, C., Dorval, M., Pashayan, N., Chiquette, J., Eloy, L., Turgeon, A., Lambert-Côté, L., Brooks, J. D., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071027 · Cited by 12
Self-citationCriteria for evaluating risk prediction of multiple outcomes
Dudbridge, F. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220929039 · Cited by 10
Eskander, A. E., Marqueen, K. E., Edwards, H., Joshua, A. M., Petrella, T. M., de Almeida, J. R., Goldstein, D. P., & Ferket, B. S. (2021) · Cancer · doi:10.1002/cncr.33499 · Cited by 12
Stankūnas, M., Pärna, K., Tisler, A., Ķīvīte‐Urtāne, A., Kojalo, U., Žodžika, J., Baltzer, N., Nygård, J. F., Nygård, M., & Uusküla, A. (2022) · Acta medica Lituanica · doi:10.15388/amed.2022.29.1.18 · Cited by 12
Zielonke, N., Geuzinge, A., Heijnsdijk, E. A. M., Heinävaara, S. H., Senore, C., Jarm, K., de Koning, H. J., & van Ravesteyn, N. T. (2021) · Cancers · doi:10.3390/cancers13133360 · Cited by 12
Loft, L. H., Pedersen, L. H., Bigaard, J., & Bojesen, S. E. (2024) · BMC Cancer · doi:10.1186/s12885-024-12083-2 · Cited by 11
Bolt, I. L. L. E., Bunnik, E. M., Tromp, K., Pashayan, N., Widschwendter, M., & de Beaufort, I. (2020) · Journal of Medical Ethics · doi:10.1136/medethics-2020-106146 · Cited by 11
Self-citationIncorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer
Shih, Y. T., Dong, W., Xu, Y., Etzioni, R., & Shen, Y. (2021) · Annals of Internal Medicine · doi:10.7326/m20-2912 · Cited by 11
Chiorino, G., Petracci, E., Šehović, E., Gregnanin, I., Camussi, E., Grand, M. M., Ostano, P., Riggi, E., Vergini, V., Russo, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38886-0 · Cited by 11
Peiffer, V., Yock, C. A., Yock, P. G., & Pietzsch, J. B. (2019) · Journal of Medical Devices · doi:10.1115/1.4042794 · Cited by 11
Harrison, H., Pennells, L. A. M., Wood, A., Rossi, S. H., Stewart, G. D., Griffin, S. J., & Usher‐Smith, J. A. (2021) · British Journal of Urology · doi:10.1111/bju.15598 · Cited by 11
Health screening needs independent regular re-evaluation
Ropers, F. G., Barratt, A. L., Wilt, T. J., Nicholls, S. G., Taylor‐Phillips, S., Kramer, B. S., Esserman, L. J., Norris, S. L., Gibson, L. M., Harris, R., et al. (2021) · BMJ · doi:10.1136/bmj.n2049 · Cited by 11
Kalia, S. S., Boddicker, N. J., Yadav, S., Huang, H., Na, J., Hu, C., Ambrosone, C. B., Yao, S., Haiman, C. A., Chen, F., et al. (2024) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-0594 · Cited by 10
Seung, S. J., Mittmann, N., Ante, Z., Liu, N., Blackmore, K. M., Richard, E. S., Wong, A., Walker, M. J., Earle, C. C., Simard, J., et al. (2024) · Cancers · doi:10.3390/cancers16183189 · Cited by 10
Kim, D. Y., & Park, H. L. (2020) · Journal of Breast Cancer · doi:10.4048/jbc.2020.23.e40 · Cited by 10
Minnis, H., Gajwani, R., & Ougrin, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.963602 · Cited by 10
Yiangou, K., Mavaddat, N., Dennis, J., Zanti, M., Wang, Q., Bolla, M. K., Abubakar, M., Ahearn, T. U., Andrulis, I. L., Anton‐Culver, H., et al. (2024) · medRxiv · doi:10.1101/2024.02.12.24302043 · Cited by 10
Estimating the Breast Cancer Burden in Germany and Implications for Risk-based Screening
Quante, A. S., Hüsing, A., Chang-Claude, J. C., Kiechle, M. B., Kaaks, R., & Pfeiffer, R. M. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0437 · Cited by 9
Miles, R. C., Chou, S.-H. S., Vijapura, C. A., & Patel, A. (2022) · Journal of Breast Imaging · doi:10.1093/jbi/wbac066 · Cited by 9
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 10
Agide, F. D., Garmaroudi, G., Sadeghi, R., Shakibazadeh, E., Yaseri, M., & Koricha, Z. B. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1377173 · Cited by 8
Walker, M. J., Neely, A., Antoniou, A. C., Broeders, M. J. M., Brooks, J. D., Carver, T. J., Chiquette, J., Easton, D. F., Eisen, A. F., Eloy, L., et al. (2025) · Current Oncology · doi:10.3390/curroncol32030155 · Cited by 8
Self-citationLambert-Côté, L., Turgeon, A., Blackmore, K. M., Chang, A., Antoniou, A. C., Bell, K. A., Broeders, M. J. M., Brooks, J. D., Carver, T. J., Chang, S.-L., et al. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101453 · Cited by 8
Self-citationSchreurs, M. A. C., y Cajal, T. R., Adank, M. A., Collée, J. M., Hollestelle, A., van Rooij, J., Schmidt, M. K., & Hooning, M. J. (2023) · The Breast · doi:10.1016/j.breast.2023.103611 · Cited by 9
Taylor, G., McWilliams, L., Woof, V. G., Evans, D. G., & French, D. (2022) · Health Expectations · doi:10.1111/hex.13637 · Cited by 8
Cui, Z., Kawasaki, H., Tsunematsu, M., Cui, Y., Rahman, M. M., Yamasaki, S., Li, Y., & Kakehashi, M. (2023) · Current Oncology · doi:10.3390/curroncol30020161 · Cited by 8
Briggs, S., & Slade, I. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-00162-x · Cited by 8
Combs, T., Tritz, D., Ivy, H., von Borstel, D., Horn, J. G., & Vassar, M. B. (2019) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2019.05.005 · Cited by 8
Byrne, P., Thetford, C., Gabbay, M., Clarke, P. M., Doncaster, E., Harding, S. P., for the ISDR Study Group, Harding, S. P., Broadbent, D., Byrne, P., et al. (2020) · BMC Public Health · doi:10.1186/s12889-020-08974-1 · Cited by 8
Badal, K., Staib, J., Tice, J. A., Kim, M., Eklund, M., Wilson, L., Byfield, S. D., Catlett, K., Maffey, L., Soonavala, R., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-089428 · Cited by 7
Mammography and Decision Aid Use for Breast Cancer Screening in Older Women
Ross, R., Rubio, K., & Rodríguez, H. P. (2022) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2022.04.014 · Cited by 7
Harms and benefits of mammographic screening for breast cancer in Brazil
Migowski, A., Nadanovsky, P., & Vianna, C. M. D. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297048 · Cited by 7
Inherited genetics of adult diffuse glioma and polygenic risk scores—a review
Eckel‐Passow, J. E., Lachance, D. H., Decker, P. A., Kollmeyer, T. M., Kosel, M., Drucker, K. L., Slager, S. L., Wrensch, M., Tobin, W. O., & Jenkins, R. B. (2022) · Neuro-Oncology Practice · doi:10.1093/nop/npac017 · Cited by 7
Hindmarch, S., Gorman, L. S., Hawkes, R. E., Howell, S. J., & French, D. (2023) · Women s Health · doi:10.1177/17455057231160348 · Cited by 7
Zhou, Y., Wu, Z. K., Zeng, L., & Chen, R. (2025) · BMC Medicine · doi:10.1186/s12916-025-04048-4 · Cited by 9
Five-Year Absolute Risk–Based and Age-Based Breast Cancer Screening in the US
Alagoz, O., Lu, Y., Quessep, E. G., Kerlikowske, K. M., Mandelblatt, J. S., Sprague, B. L., Trentham‐Dietz, A., Hampton, J. M., Groeneweg, R., de Koning, H. J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.52944 · Cited by 6
Yang, D.-W., Miller, J. A., Xue, W., Tang, M., Lei, L., Zheng, Y., Diao, H., Wang, T., Liao, Y., Wu, Y., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1375533 · Cited by 6
Jones, C. K., Scott, S. E., & Waller, J. (2024) · BMC Cancer · doi:10.1186/s12885-024-12847-w · Cited by 6
Harms and Benefits of Cancer Screening
Robra, B. (2021) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-63749-1_7 · Cited by 6
Hennessy, G., Boland, M. R., Bambrick, M., Crone, L., Lloyd, A., Elwahab, S. M. A., Downey, E., Staunton, M., Hambly, N. M., Mhuircheartaigh, N. N., et al. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.05.009 · Cited by 6
Anandarajah, A., Chen, Y., Stoll, C. R. T., Hardi, A., Jiang, S., & Colditz, G. A. (2023) · Cancer Causes & Control · doi:10.1007/s10552-023-01739-2 · Cited by 6
Svyatova, G., Berezina, G., Urazbayeva, G., & Murtazaliyeva, A. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.11.3899 · Cited by 6
Estimating disorder probability based on polygenic prediction using the BPC approach
Uffelmann, E., Lewis, C. M., McIntosh, A. M., O’Donovan, M. C., Walters, J., Price, A. L., Posthuma, D., & Peyrot, W. J. (2025) · Nature Communications · doi:10.1038/s41467-025-62929-x · Cited by 6
Precision risk-based screening might maximize benefit and minimize harm
Esserman, L. J., & LaCroix, A. Z. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0093-0 · Cited by 6
O’Mahony, J. F. (2021) · Medical Decision Making · doi:10.1177/0272989x211050918 · Cited by 6
Evans, D. G., Howell, S. J., & Howell, A. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.012 · Cited by 6
Concerns About Methods Used in Modeling Study of Risk-Stratified Screening for Breast Cancer
Pashayan, N., & Pharoah, P. D. P. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.7311 · Cited by 6
Self-citationAtrial Fibrillation Screening According to Genetic Risk
Vad, O. B., Diederichsen, S. Z., Xing, L. Y., Paludan‐Müller, C., Monfort, L. M., Ahlberg, G., Andreasen, L., Haugan, K., Graff, C., Højberg, S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.024 · Cited by 6
Noguchi, N., Marinovich, M. L., Wylie, E. J., Lund, H., & Houssami, N. (2022) · The Breast · doi:10.1016/j.breast.2022.01.015 · Cited by 5
Jones, C. K., Scott, S. E., Pashayan, N., Stephen Morris, A., Okan, Y., & Waller, J. (2024) · Medical Decision Making · doi:10.1177/0272989x241254828 · Cited by 5
Self-citationOmeranovic, A., Lapointe, J., Fortier, P., Bergeron, A.-S., Dorval, M., Chiquette, J., Boubaker, A., Eloy, L., Turgeon, A., Lambert-Côté, L., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-093936 · Cited by 5
Self-citationRamsay, G., Brooks, R., Wade, C., Liew, J. J. M., Alphonse, P., McIntosh, J., Forrest, L. E., Emery, J. D., & Saya, S. (2025) · British Journal of General Practice · doi:10.3399/bjgp.2025.0159 · Cited by 5
Raoof, S., Kansal, A. R., Tafazzoli, A., Ye, W., Morris, W., Zou, D., & Fendrick, A. M. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-25-0610 · Cited by 5
A systematic review of prediction models for risk of breast cancer
Re, F., Manaboriboon, N., Raza, I. G. A., Shipley, A., Thompson, L., Tiplady, C., Blum, M., Blum, G., Mucheke, R., Abhari, R. E., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14990-4 · Cited by 7
Robustness of risk-based allocation of resources for disease prevention
Gail, M. H., & Pee, D. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220930055 · Cited by 5
Risk stratification in breast screening workshop
Anderson, A., Visintin, C., Antoniou, A. C., Pashayan, N., Gilbert, F. J., Hackshaw, A. K., Bhatt, R., Hill, H. R., Wright, S. J., Payne, K., et al. (2024) · BMC Proceedings · doi:10.1186/s12919-024-00306-0 · Cited by 5
Self-citationDelaloge, S., & Balleyguier, C. (2019) · Imagerie de la Femme · doi:10.1016/j.femme.2019.02.001 · Cited by 5
Breast Cancer Susceptibility—Towards Individualised Risk Prediction
Lakeman, I. M. M., Schmidt, M. K., van Asperen, C. J., & Devilee, P. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-00168-5 · Cited by 5
Jalilian, F., Jerome-D’Emilia, B., Najafi, F., Pasdar, Y., Matin, B. K., Amini, M., Kargar, M., Moradinazar, M., Pirouzeh, R., Karimi, N., et al. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.5.1555 · Cited by 5
Rebitschek, F. G., Pashayan, N., Widschwendter, M., & Wegwarth, O. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218188 · Cited by 5
Self-citationClinical Implementation Study of Genetic Risk-Based Breast Cancer Screening
Tamm, M., Padrik, P., Ojamaa, K., Paas, A., Lepland, A., Kruuv-Käo, K., Leitsalu, L., Sõber, S., Roht, L., Pajusalu, S., et al. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.08.021 · Cited by 4
Prediction Models for Falls Risk Among Inpatients: A Systematic Review and Meta‐Analysis
Zhao, G., Zhang, Y., Luo, J., Tong, Y., & Sui, W. (2025) · Journal of Advanced Nursing · doi:10.1111/jan.17079 · Cited by 4
Purvis, R., Taylor, N. J., Young, M., James, P. A., & Forrest, L. E. (2025) · Clinical and Translational Science · doi:10.1111/cts.70323 · Cited by 4
Using Risk Stratification to Optimize Mammography Screening in Chinese Women
Leung, K. S. M., Wu, J. T. K., Wong, I. O.-L., Shu, X., Zheng, W., Wen, W., Khoo, U., Ngan, R. K. C., Kwong, A., & Leung, G. M. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab060 · Cited by 4
The Role of Family History and Germline Genetics in Prostate Cancer Disease Profile and Screening
Raghallaigh, H. N., & Bott, S. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications-urologic-cancers-prostate-cancer-family-history-genetics · Cited by 4
Fehlberg, Z., Fisher, L., Liu, C., Kugenthiran, N., Milne, R. L., Young, M., Willis, A. M., Southey, M. C., Goranitis, I., & Best, S. (2024) · European Journal of Human Genetics · doi:10.1038/s41431-024-01729-1 · Cited by 4
Trapani, D., Sandoval, J. L. B. R. G., Aliaga, P. T., Ascione, L., Giachetti, P. P. M. B., Curigliano, G., & Ginsburg, O. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_3 · Cited by 4
Metadata
- Authors
- Pashayan, N., Morris, S., Gilbert, F. J., & Pharoah, P. D. P.
- Affiliations
- University College London (GB)
- Department of Applied Health Research, University College London, London, England
- University of Cambridge (GB)
- Corresponding author
- Pashayan, Nora
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-11-01
- Volume
- 4
- Issue
- 11
- Pages
- 1504
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6230256
- OpenAlex
- W2829068939
- Cited by
- 284
- References
- 25
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 35 · 2023: 31 · 2022: 48 · 2021: 49 · 2020: 31 · 2019: 35 · 2018: 8
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- JAMA Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (10119, 16561, C490/A16561, 26884, A16561)
- National Institute for Health and Care Research (NF-SI-0515-10067)
- Engineering and Physical Sciences Research Council (EP/P006485/1)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Digital Radiography and Breast Imaging
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- breast cancer screening, risk-stratified screening, mammography, overdiagnosis, cost-effectiveness, polygenic risk score, risk thresholds, breast cancer mortality, quality-adjusted life years, net monetary benefit, life table model, women aged 50-69, National Health Service, willingness-to-pay threshold
- MeSH terms
- Aged, Breast Neoplasms, Cost-Benefit Analysis, Female, Humans, Middle Aged, Risk Assessment, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
